Drugmakers Merck, Allergan Spark Rumors Of Biogen Takeover A Wall Street Journal report stokes speculations that biotech company Biogen is the acquisition target of two larger drugmakers. Allergan and Merck are each vying for the company. by Rachel Ranosa
Business Tech Pfizer Kills $160 Billion Deal With Allergan Amid Crackdown On Corporate Inversions by Milafel Dacanay
Business Tech Pfizer, Allergan Considering Blockbuster Merger: Combined Company Would Have $332B Market Cap by Aaron Mamiit